ABSTRACT
Coronary artery disease (CAD) and peripheral artery disease (PAD) are common and dangerous conditions that are both driven by atherosclerosis. Despite sharing many major risk factors, their disease pathophysiology is not fully understood. In this study, we aimed to better distinguish common vs. unique biological pathways underlying CAD and PAD by proteomics profiling plasma samples from a subset of participants in the Project Baseline Health Study (PBHS). We identified 14 proteins associated with coronary artery calcium (CAC) score ≥100 and 39 proteins associated with the ankle brachial index (ABI) after covariate adjustment. Two proteins (complement component 7 [C7] and polymeric immunoglobulin receptor [PIGR]) were significantly associated with both CAC and ABI. Our work highlights the potential molecular pathways unique to these diseases, which could have therapeutic implications for personalizing clinical management.
Competing Interest Statement
All authors acknowledge institutional research grants from Verily Life Sciences. KM reports grants from Verily, Afferent, the American Heart Association (AHA), Cardiva Medical Inc, Gilead, Luitpold, Medtronic, Merck, Eidos, Ferring, Apple Inc, Sanifit, and St. Jude; grants and personal fees from Amgen, AstraZeneca, Bayer, CSL Behring, Johnson & Johnson, Novartis, and Sanofi; and personal fees from Anthos, Applied Therapeutics, Elsevier, Inova, Intermountain Health, Medscape, Mount Sinai, Mundi Pharma, Myokardia, Novo Nordisk, Otsuka, Portola, SmartMedics, and Theravance outside the submitted work. AH reports grants from Verily; grants and personal fees from AstraZeneca, Amgen, Bayer, Merck, and Novartis; and personal fees from Boston Scientific outside the submitted work. SHS receives research funding through a sponsored research agreement to Duke University from AstraZeneca, Lilly Inc., nference Inc., Owkin, and Verily, and holds two patents on unrelated research findings. The other authors have no conflicts of interest to disclose.
Funding Statement
The Baseline Health Study and this analysis were funded by Verily Life Sciences, South San Francisco, California. Kalyani Kottilil is funded by a National Institutes of Health (NIH) F31 grant [1F31HL175914-01].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Duke University and Stanford University Institutional Review Boards. Informed consent was obtained from all participants enrolled in the Project Baseline Health Study in accordance with the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The deidentified PBHS data corresponding to this study are available upon request for the purpose of examining its reproducibility. Requests are subject to approval by PBHS governance.
